AMG 176 is an MCL-1 inhibitor (myeloid cell leukemia-1) that can prevent cancer cells from creating proteins to protect itself, and can cause cell death.
| SparkCures ID | 263 |
|---|---|
| Developed By | Amgen |
| Generic Name | AMG 176 |
| Treatment Classifications |
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
There are no resources, links or videos to display for this treatment.